Tolinapant is under clinical development by Taiho Pharmaceutical and currently in Phase I for Hepatocellular Carcinoma.

TAS-1440 is under clinical development by Taiho Pharmaceutical and currently in Phase I for Refractory Acute Myeloid Leukemia.

“We’re open for business,” said Taiho Oncology, Inc. CEO, Timothy Whitten. Alongside its growing pipeline of orally administered oncology drugs, the US subsidiary of Japan’s Taiho ...

Oho, making his debut in the highest makuuchi division, is a grandson of Taiho, the late yokozuna of the Showa Era (1926-1989), who dominated sumo in postwar Japan. Oho’s father is ...

Taiho Oncology. "When administered at home, HMAs such as ASTX030 and INQOVI may potentially reduce the toll of time toxicity many patients with cancer experience and may help them to manage this ...

PRINCETON, N.J., Dec. 9, 2024 /PRNewswire/ -- Taiho Oncology, Inc., presented results of two studies focused on oral therapies for patients with myelodysplastic syndromes (MDS) and MDS ...

"We're pleased to join hematology scientific leaders at the ASH meeting to share data on oral HMAs for patients living with complications from MDS," said Harold Keer, MD, PhD, Chief Medical Officer, ...